Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (538) 538
Publication (29) 29
Book Review (8) 8
Newsletter (7) 7
Newspaper Article (6) 6
Magazine Article (2) 2
Book Chapter (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (414) 414
tiotropium (409) 409
pulmonary disease, chronic obstructive - drug therapy (352) 352
index medicus (339) 339
respiratory system (280) 280
male (275) 275
female (265) 265
tiotropium bromide (263) 263
copd (256) 256
lung diseases, obstructive (229) 229
middle aged (226) 226
aged (217) 217
chronic obstructive pulmonary disease (215) 215
obstructive pulmonary-disease (209) 209
bronchodilator agents - therapeutic use (203) 203
administration, inhalation (198) 198
bronchodilator agents - administration & dosage (187) 187
treatment outcome (187) 187
pulmonary disease, chronic obstructive - physiopathology (174) 174
scopolamine derivatives - therapeutic use (158) 158
drug therapy (155) 155
bronchodilator agents - adverse effects (143) 143
double-blind method (139) 139
scopolamine derivatives - administration & dosage (118) 118
pharmacology & pharmacy (115) 115
salmeterol (112) 112
efficacy (111) 111
safety (109) 109
care and treatment (103) 103
asthma (101) 101
forced expiratory volume (97) 97
mortality (96) 96
dosage and administration (91) 91
respiratory tract diseases (91) 91
research (90) 90
drug therapy, combination (89) 89
pulmonary/respiratory (88) 88
scopolamine derivatives - adverse effects (86) 86
exacerbations (84) 84
quality of life (83) 83
pulmonary disease, chronic obstructive - diagnosis (82) 82
adult (81) 81
clinical trials (75) 75
lung-function (75) 75
pulmonary and respiratory medicine (71) 71
forced expiratory volume - drug effects (70) 70
formoterol (68) 68
tiotropium bromide - administration & dosage (67) 67
original research (66) 66
severity of illness index (66) 66
analysis (64) 64
diseases of the respiratory system (64) 64
spirometry (64) 64
time factors (63) 63
lung - physiopathology (62) 62
muscarinic antagonists - administration & dosage (62) 62
cardiac & cardiovascular systems (60) 60
drug administration schedule (58) 58
respiratory agents (58) 58
cross-over studies (56) 56
muscarinic antagonists - adverse effects (56) 56
nebulizers and vaporizers (56) 56
lung - drug effects (55) 55
aged, 80 and over (54) 54
muscarinic antagonists - therapeutic use (54) 54
bronchodilator (52) 52
drug combinations (52) 52
bronchodilators (49) 49
respimat (48) 48
therapy (48) 48
cholinergic antagonists - therapeutic use (47) 47
dyspnea (47) 47
albuterol - analogs & derivatives (46) 46
asthma - drug therapy (46) 46
randomized controlled trials as topic (46) 46
risk (46) 46
cholinergic antagonists - administration & dosage (45) 45
risk factors (45) 45
tiotropium bromide - adverse effects (45) 45
tiotropium bromide - therapeutic use (45) 45
ipratropium (44) 44
salmeterol xinafoate (44) 44
studies (44) 44
double-blind (43) 43
medicine, general & internal (43) 43
trial (43) 43
adrenergic beta-2 receptor agonists - administration & dosage (42) 42
combination (42) 42
drug dosages (42) 42
patients (42) 42
albuterol - therapeutic use (41) 41
bromide (41) 41
cholinergic antagonists - adverse effects (41) 41
international journal of chronic obstructive pulmonary disease (41) 41
complications and side effects (40) 40
disease progression (40) 40
health outcomes (40) 40
respiratory function tests (40) 40
abridged index medicus (39) 39
adrenergic beta-2 receptor agonists - therapeutic use (39) 39
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (545) 545
Korean (2) 2
Russian (2) 2
Chinese (1) 1
French (1) 1
German (1) 1
Japanese (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Tiotropium handihaler® and respimat®in copd: A pooled safety analysis
by Halpin, David M. G and Dahl, Ronald and Hallmann, Christoph and Mueller, Achim and Tashkin, Donald
International Journal of COPD, ISSN 1176-9106, 02/2015, Volume 10, pp. 239 - 259
Introduction: Tiotropium is prescribed for the treatment of chronic obstructive pulmonary disease (COPD) and delivered via HandiHaler (R) (18 mu g once daily)... 
HandiHaler | Tiotropium | Respimat | EFFICACY | CARDIOVASCULAR EVENTS | AIR-FLOW | EXERCISE TOLERANCE | Respimat (R) | tiotropium | ONCE-DAILY TIOTROPIUM | OBSTRUCTIVE PULMONARY-DISEASE | HandiHaler (R) | RESPIRATORY SYSTEM | EXACERBATIONS | INHALATION POWDER | INHALED ANTICHOLINERGICS | HEALTH OUTCOMES | Pulmonary Disease, Chronic Obstructive - mortality | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Equipment Design | Forced Expiratory Volume | Time Factors | Patient Safety | Scopolamine Derivatives - administration & dosage | Female | Bronchodilator Agents - adverse effects | Odds Ratio | Scopolamine Derivatives - adverse effects | Tiotropium Bromide | Pulmonary Disease, Chronic Obstructive - diagnosis | Risk Factors | Administration, Inhalation | Treatment Outcome | Lung - physiopathology | Randomized Controlled Trials as Topic | Muscarinic Antagonists - administration & dosage | Vital Capacity | Lung - drug effects | Aged | Nebulizers and Vaporizers | Pulmonary Disease, Chronic Obstructive - drug therapy | Clinical trials | Complications and side effects | Lung diseases, Obstructive | Management | Drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Patients' perspectives and preferences in the choice of inhalers: the case for Respimat((R)) or HandiHaler((R))
by Dekhuijzen, P.N.R and Lavorini, F and Usmani, O.S
Patient Preference and Adherence, ISSN 1177-889X, 2016, Volume 10, pp. 1561 - 1572
Poor inhaler technique hampers the efficacy of drug therapy in asthma and chronic obstructive pulmonary disease. Not only does this affect individual patient... 
Chronic obstructive pulmonary disease | Tiotropium Respimat | Soft Mist™ Inhaler | Inhaler technique | Tiotropium HandiHaler | Asthma | PULMONARY DRUG-DELIVERY | MANAGEMENT | INHALATION DEVICES | GUIDELINES | Soft Mist (TM) Inhaler | inhaler technique | asthma | CARE | SOFT MIST(TM) INHALER | AEROSOL THERAPY | MEDICINE, GENERAL & INTERNAL | tiotropium HandiHaler (R) | METERED-DOSE INHALERS | chronic obstructive pulmonary disease | tiotropium Respimat (R) | COPD | Respiratory agents | Care and treatment | Drug therapy | Patients | Patient compliance | tiotropium HandiHaler | tiotropium Respimat
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Tiotropium Respimat® vs. HandiHaler®: real‐life usage and TIOSPIR trial generalizability
by Schmiedl, Sven and Fischer, Rainald and Ibanez, Luisa and Fortuny, Joan and Thürmann, Petra and Ballarin, Elena and Ferrer, Pili and Sabaté, Monica and Rottenkolber, Dominik and Gerlach, Roman and Tauscher, Martin and Reynolds, Robert and Hasford, Joerg and Rottenkolber, Marietta
British Journal of Clinical Pharmacology, ISSN 0306-5251, 02/2016, Volume 81, Issue 2, pp. 379 - 388
Aim Two inhaler devices (Respimat® and HandiHaler®) are available for tiotropium, a long acting anticholinergic agent. We aimed to analyze drug utilization,... 
real‐life usage | TIOSPIR trial | secondary data analysis | COPD | tiotropium | real-life usage | MORTALITY | RANDOMIZED CONTROLLED-TRIALS | POPULATION | METAANALYSIS | INHALER DEVICES | RISK | PRACTITIONERS | OBSTRUCTIVE PULMONARY-DISEASE | ASTHMA | PHARMACOLOGY & PHARMACY | COPD PATIENTS | Dry Powder Inhalers | Humans | Administration, Inhalation | Male | Clinical Trials as Topic | Cholinergic Antagonists - administration & dosage | Tiotropium Bromide - administration & dosage | Metered Dose Inhalers | Female | Tiotropium Bromide - therapeutic use | Aged | Cholinergic Antagonists - therapeutic use | Drug Utilization - statistics & numerical data | Off-Label Use - statistics & numerical data | Databases, Factual | Pulmonary Disease, Chronic Obstructive - drug therapy | Usage | Lung diseases, Obstructive | Information management | Index Medicus | Pharmacoepidemiology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text The efficacy of tiotropium administered via Respimat® Soft Mist™ Inhaler or HandiHaler® in COPD patients
by van Noord, J.A and Cornelissen, P.J.G and Aumann, J.-L and Platz, J and Mueller, A and Fogarty, C
Respiratory Medicine, ISSN 0954-6111, 2008, Volume 103, Issue 1, pp. 22 - 29
Summary Background Tiotropium, a once daily inhaled anticholinergic delivered via HandiHaler® , provides bronchodilation for >24 h and improves patient-centred... 
Pulmonary/Respiratory | Bronchodilators | Anticholinergics | Tiotropium | Respimat | Chronic obstructive pulmonary disease | Inhalation therapy | Bronchodilator Agents - therapeutic use | Bronchodilator Agents - administration & dosage | Double-Blind Method | Drug Administration Schedule | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Administration, Inhalation | Male | Metabolic Clearance Rate | Treatment Outcome | Pulmonary Disease, Chronic Obstructive - physiopathology | Cross-Over Studies | Bronchodilator Agents - pharmacokinetics | Pulmonary Disease, Chronic Obstructive - blood | Scopolamine Derivatives - administration & dosage | Metered Dose Inhalers | Female | Aged | Scopolamine Derivatives - pharmacokinetics | Scopolamine Derivatives - therapeutic use | Pulmonary Disease, Chronic Obstructive - drug therapy | Tiotropium Bromide | Clinical trials | Lungs | Oxygen therapy | Drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Efficacy and safety of combining olodaterol Respimat® and tiotropium HandiHaler® in patients with COPD: Results of two randomized, double-blind, active-controlled studies
by ZuWallack, Richard and Allen, Lisa and Hernandez, Gemzel and Ting, Naitee and Abrahams, Roger
International Journal of COPD, ISSN 1176-9106, 10/2014, Volume 9, pp. 1133 - 1144
Background: Combining bronchodilators with different mechanisms of action may improve efficacy and reduce risk of side effects compared to increasing the dose... 
Olodaterol Respimat | Long-acting muscarinic antagonist | Bronchodilator | Long-acting beta2-agonist | Tiotropium HandiHaler | INDACATEROL | TRIALS | OBSTRUCTIVE PULMONARY-DISEASE | MANAGEMENT | long-acting beta2-agonist | RESPIRATORY SYSTEM | tiotropium HandiHaler (R) | long-acting muscarinic antagonist | bronchodilator | olodaterol Respimat (R) | Spirometry | Bronchodilator Agents - administration & dosage | United States | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Equipment Design | Forced Expiratory Volume | Time Factors | Adrenergic beta-2 Receptor Agonists - adverse effects | Scopolamine Derivatives - administration & dosage | Female | Surveys and Questionnaires | Bronchodilator Agents - adverse effects | Drug Therapy, Combination | Scopolamine Derivatives - adverse effects | Tiotropium Bromide | Pulmonary Disease, Chronic Obstructive - diagnosis | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Administration, Inhalation | Benzoxazines - adverse effects | Treatment Outcome | Lung - physiopathology | Muscarinic Antagonists - administration & dosage | Lung - drug effects | Adrenergic beta-2 Receptor Agonists - administration & dosage | Aged | Nebulizers and Vaporizers | Pulmonary Disease, Chronic Obstructive - drug therapy | Tiotropium | Lung diseases, Obstructive | Research | Drug therapy, Combination | Drug therapy | Health aspects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Tiotropium Respimat® Versus HandiHaler®: Comparison of Bronchodilator Efficacy of Various Doses in Clinical Trials
by Calverley, Peter M. A and Könen-Bergmann, Michael and Richard, Frank and Bell, Susan and Hohlfeld, Jens M
Advances in Therapy, ISSN 0741-238X, 5/2016, Volume 33, Issue 5, pp. 786 - 793
The long-acting muscarinic antagonist tiotropium bromide is approved in many countries as maintenance therapy for chronic obstructive pulmonary disease (COPD).... 
Pulmonology | Chronic obstructive pulmonary disease (COPD) | Spirometry | Dose–response | Long-acting muscarinic antagonist | Bronchodilator | Rheumatology | Internal Medicine | Oncology | Efficacy | Respimat | Tiotropium | Lung function | Medicine & Public Health | Once-daily | Cardiology | Pharmacology/Toxicology | Endocrinology | MEDICINE, RESEARCH & EXPERIMENTAL | SAFETY | PERFORMANCE | Respimat (R) | INHALER | OBSTRUCTIVE PULMONARY-DISEASE | TIOSPIR(R) | Dose-response | PHARMACOLOGY & PHARMACY | COPD PATIENTS | Bronchodilator Agents - administration & dosage | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Tiotropium Bromide - adverse effects | Administration, Inhalation | Male | Treatment Outcome | Muscarinic Antagonists - therapeutic use | Tiotropium Bromide - pharmacokinetics | Dose-Response Relationship, Drug | Tiotropium Bromide - administration & dosage | Bronchodilator Agents - pharmacokinetics | Female | Aged | Bronchodilator Agents - adverse effects | Drug Monitoring | Pulmonary Disease, Chronic Obstructive - drug therapy | Original Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: Does inhaler choice matter?
by Dahl, Ronald and Kaplan, Alan
BMC Pulmonary Medicine, ISSN 1471-2466, 10/2016, Volume 16, Issue 1, p. 135
Background: In many countries worldwide, the long-acting anticholinergic drug tiotropium is available as a dry powder formulation delivered by means of the... 
Chronic obstructive pulmonary disease | Tiotropium Respimat | Soft Mist™ Inhaler | Tiotropium HandiHaler | Tiotropium HandiHaler (R) | MORTALITY | CARDIAC SAFETY | EFFICACY | PERFORMANCE | DEPOSITION | Soft Mist (TM) Inhaler | TIOSPIR(TM) SAFETY | Tiotropium Respimat (R) | SOFT MIST(TM) INHALER | AEROSOL | RESPIRATORY SYSTEM | POWDER | COPD | Forced Expiratory Volume | Tiotropium Bromide - administration & dosage | Bronchodilator Agents - administration & dosage | Humans | Administration, Inhalation | Metered Dose Inhalers | Lung - physiopathology | Patient Preference | Pulmonary Disease, Chronic Obstructive - physiopathology | Pulmonary Disease, Chronic Obstructive - drug therapy | Randomized Controlled Trials as Topic | Drugs | Tiotropium | Drug delivery systems | Usage | Lung diseases, Obstructive | Care and treatment | Physicians | Practice | Dosage and administration | Drug therapy | Vehicles
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD
by Verhamme, Katia M. C and Afonso, Ana and Romio, Silvana and Stricker, Bruno C and Brusselle, Guy G. O and Sturkenboom, Miriam C. J. M
European Respiratory Journal, ISSN 0903-1936, 09/2013, Volume 42, Issue 3, pp. 606 - 615
Tiotropium, a long-acting anticholinergic, is delivered via HandiHaler or via Respimat. Randomised controlled trials suggest that use of tiotropium Respimat... 
BRONCHODILATOR | RANDOMIZED CONTROLLED-TRIALS | OBSTRUCTIVE PULMONARY-DISEASE | METAANALYSIS | MEDICATIONS | RESPIRATORY SYSTEM | VALIDATION | RISK | DEATH | HEALTH OUTCOMES | SALMETEROL | Pulmonary Disease, Chronic Obstructive - mortality | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Proportional Hazards Models | Administration, Inhalation | Male | Treatment Outcome | Dry Powder Inhalers - adverse effects | Scopolamine Derivatives - administration & dosage | Female | Aged | Bronchodilator Agents - adverse effects | Drug Delivery Systems - adverse effects | Scopolamine Derivatives - adverse effects | Cohort Studies | Databases, Factual | Pulmonary Disease, Chronic Obstructive - drug therapy | Tiotropium Bromide
Journal Article
Details down arrow
9. Full Text Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: A randomized cross-over trial
by Altman, Pablo and Wehbe, Luis and Dederichs, Juergen and Guerin, Tadhg and Ament, Brian and Moronta, Miguel Cardenas and Pino, Andrea Valeria and Goyal, Pankaj
BMC Pulmonary Medicine, ISSN 1471-2466, 06/2018, Volume 18, Issue 1, pp. 100 - 8
Background: The chronic and progressive nature of chronic obstructive pulmonary disease (COPD) requires self-administration of inhaled medication. Dry powder... 
Dry powder inhalers | Peak inspiratory flow | Pressure drop | Breezhaler | Inspiratory effort | OBSTRUCTIVE PULMONARY-DISEASE | Breezhaler (R) | DRUG-DELIVERY | RESPIRATORY SYSTEM | DELIVERY CHARACTERISTICS | RESISTANCE | DEVICES | Severity of Illness Index | Pulmonary Disease, Chronic Obstructive - diagnosis | Age Factors | Outcome Assessment (Health Care) | Humans | Middle Aged | Respiratory Therapy - methods | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Airway Resistance | Equipment Design | Respiratory Therapy - instrumentation | Cross-Over Studies | Pulmonary Disease, Chronic Obstructive - therapy | Self Administration - methods | Dry Powder Inhalers - instrumentation | Smoking - physiopathology | Sex Factors | Work of Breathing | Female | Self Administration - instrumentation | Aged | Inspiratory Capacity | Dry Powder Inhalers - methods | Respiratory therapy | Tiotropium | Lung diseases, Obstructive | Care and treatment | Usage | Indacaterol | Dosage and administration | Comparative analysis | Inhalers
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Tiotropium HandiHaler in the treatment of COPD: a safety review
by Kesten, Steven and Celli, Bart and Decramer, Marc and Leimer, Inge and Tashkin, Donald
International journal of chronic obstructive pulmonary disease, ISSN 1178-2005, 2009, Volume 4, pp. 397 - 409
Tiotropium is a long-acting inhaled anticholinergic developed for the treatment of chronic obstructive pulmonary disease (COPD) and has been available since... 
Humans | Middle Aged | Male | Treatment Outcome | Clinical Trials as Topic | Cholinergic Antagonists - administration & dosage | Drug-Related Side Effects and Adverse Reactions | Scopolamine Derivatives - administration & dosage | Female | Aged | Cholinergic Antagonists - adverse effects | Nebulizers and Vaporizers | Scopolamine Derivatives - adverse effects | Pulmonary Disease, Chronic Obstructive - drug therapy | Tiotropium Bromide | mortality | Review | safety | tiotropium | chronic obstructive pulmonary disease
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Tiotropium 5 μg via Respimat and 18 μg via HandiHaler; efficacy and safety in Japanese COPD patients
by Ichinose, M and Fujimoto, T and Fukuchi, Y
Respiratory Medicine, ISSN 0954-6111, 2009, Volume 104, Issue 2, pp. 228 - 236
Summary Background and objectives To compare the efficacy and safety of tiotropium inhaled via Respimat® Soft Mist Inhaler, a multidose propellant-free inhaler... 
Pulmonary/Respiratory | Bronchodilators | Tiotropium | Inhalation devices | Pharmacokinetics | COPD
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Effect of Switching Tiotropium HandiHaler® to Respimat® Soft Mist™ Inhaler in Patients with COPD: The Difference of Adverse Events and Usability Between Inhaler Devices
by Asakura, Yuka and Nishimura, Naoki and Maezawa, Kayoko and Terajima, Tomoko and Kizu, Junko and Chohnabayashi, Naohiko
Journal of Aerosol Medicine and Pulmonary Drug Delivery, ISSN 1941-2711, 02/2013, Volume 26, Issue 1, pp. 41 - 45
Background: Recently, tiotropium Respimat ® Soft Mist ™ Inhaler has been developed. Respimat is a multidose and propellant-free kit. The aerosol generated from... 
Original Research | HandiHaler | Respimat | chronic obstructive pulmonary disease (COPD) | tiotropium | HandiHaler (R) | EFFICACY | Respimat (R) | RESPIRATORY SYSTEM | Prospective Studies | Bronchodilator Agents - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Administration, Inhalation | Male | Dyspnea - etiology | Equipment Design | Dyspnea - epidemiology | Forced Expiratory Volume | Cough - etiology | Scopolamine Derivatives - administration & dosage | Aged, 80 and over | Aged | Xerostomia - etiology | Bronchodilator Agents - adverse effects | Xerostomia - epidemiology | Scopolamine Derivatives - therapeutic use | Nebulizers and Vaporizers | Scopolamine Derivatives - adverse effects | Cohort Studies | Pulmonary Disease, Chronic Obstructive - drug therapy | Tiotropium Bromide
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Cardiovascular safety of tiotropium Respimat vs HandiHaler in the routine clinical practice: A population-based cohort study
by Trotta, Francesco and Spila-Alegiani, Stefania and Da Cas, Roberto and Rajevic, Maja and Conti, Valentino and Venegoni, Mauro and Rossi, Mariangela and Traversa, Giuseppe
PLoS ONE, ISSN 1932-6203, 04/2017, Volume 12, Issue 4, p. e0176276
The cardiovascular safety of tiotropium Respimat formulation in the routine clinical practice is still an open issue. Our aim was to compare the risk of acute... 
MORTALITY | MEDICATIONS | MULTIDISCIPLINARY SCIENCES | TIOSPIR TRIAL | INCREASES | RISK | DEATH | PRO | MIST INHALER | COPD | Bronchodilator Agents - therapeutic use | Tiotropium Bromide - administration & dosage | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Aged, 80 and over | Female | Male | Tiotropium Bromide - therapeutic use | Aged | Cohort Studies | Tiotropium | Complications and side effects | Dosage and administration | Research | Heart attack | Risk factors | Formulations | Myocardial infarction | Heart | Mortality | Disorders | Clinical trials | Rhythm | Population studies | Patients | Infarction | Chronic obstructive pulmonary disease | Safety | Health risk assessment | Pharmaceuticals
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text The efficacy of tiotropium administered via Respimat (R) Soft MistT (TM) Inhaler or HandiHaler (R) in COPD patients
by van Noord, JA and Cornelissen, PJG and Aumann, JL and Platz, J and Mueller, A and Fogarty, C
RESPIRATORY MEDICINE, ISSN 0954-6111, 01/2009, Volume 103, Issue 1, pp. 22 - 29
Background: Tiotropium, a once daily inhaled anticholinergic delivered via HandiHaler (R), provides bronchodilation for >24 h and improves patient-centred... 
CARDIAC & CARDIOVASCULAR SYSTEMS | Inhalation therapy | SAFETY | PERFORMANCE | LUNG-FUNCTION | EXERCISE TOLERANCE | Respimat (R) | COMBINATION | SALMETEROL | ONCE-DAILY TIOTROPIUM | Anticholinergics | Tiotropium | OBSTRUCTIVE PULMONARY-DISEASE | RESPIRATORY SYSTEM | Bronchodilators | Chronic obstructive pulmonary disease | FLUTICASONE | HEALTH OUTCOMES
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial
by Dahl, Ronald and Calverley, Peter M A and Anzueto, Antonio and Metzdorf, Norbert and Fowler, Andy and Mueller, Achim and Wise, Robert and Dusser, Daniel
BMJ Open, ISSN 2044-6055, 12/2015, Volume 5, Issue 12, p. e009015
ObjectivesThis post hoc analysis of TIOtropium Safety and Performance In Respimat (TIOSPIR) evaluated safety and exacerbation efficacy in patients with stable... 
MORTALITY | RANDOMIZED CONTROLLED-TRIALS | METAANALYSIS | Efficacy | RISK | Respimat (R) | Switching | Tiotropium | MEDICINE, GENERAL & INTERNAL | OBSTRUCTIVE PULMONARY-DISEASE | HandiHaler (R) | CLINICAL-TRIALS | POWDER | MIST INHALER | COPD | Pulmonary Disease, Chronic Obstructive - mortality | Bronchodilator Agents - administration & dosage | Double-Blind Method | Humans | Middle Aged | Risk Factors | Tiotropium Bromide - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Administration, Inhalation | Male | Treatment Outcome | International Cooperation | Equipment Design | Disease Progression | Forced Expiratory Volume | Tiotropium Bromide - administration & dosage | Female | Aged | Bronchodilator Agents - adverse effects | Nebulizers and Vaporizers | Pulmonary Disease, Chronic Obstructive - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Assessment of patient performance of the HandiHaler ® compared with the metered dose inhaler four weeks after instruction
by Dahl, R and Backer, V and Ollgaard, B and Gerken, F and Kesten, S
Respiratory Medicine, ISSN 0954-6111, 2003, Volume 97, Issue 10, pp. 1126 - 1133
The HandiHaler® is a novel breath-actuated dry powder system designed for the delivery of tiotropium 18 μg daily in the treatment of COPD. We compared patient... 
Tiotropium | Chronic obstructive pulmonary disease | Performance | Inhaler technique | Device | Bronchodilator | CARDIAC & CARDIOVASCULAR SYSTEMS | performance | RESPIRATORY SYSTEM | KNOWLEDGE | inhaler technique | POWDER | device | bronchodilator | chronic obstructive pulmonary disease | tiotropium | DELIVERY | COPD | Single-Blind Method | Age Factors | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Patient Participation | Administration, Inhalation | Male | Treatment Outcome | Nebulizers and Vaporizers - standards | Scopolamine Derivatives - administration & dosage | Sex Factors | Aged, 80 and over | Metered Dose Inhalers | Adult | Female | Aged | Patient Education as Topic | Pulmonary Disease, Chronic Obstructive - drug therapy | Tiotropium Bromide | Respiratory therapy | Drug dosages | Evacuations & rescues
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Bronchodilator efficacy of 18 μg once-daily tiotropium inhalation via Discair® versus HandiHaler® in adults with chronic obstructive pulmonary disease: Randomized, active-controlled, parallel-group, open-label, Phase IV trial
by Yildiz, Pinar and Bayraktaroglu, Mesut and Gorgun, Didem and Secik, Funda
International Journal of COPD, ISSN 1176-9106, 11/2016, Volume 11, Issue 1, pp. 2859 - 2867
To compare the bronchodilator efficacy of 18 μg once-daily tiotropium inhalation administered via Discair versus HandiHaler in adults with moderate-to-severe... 
HandiHaler | Spirometry | Tiotropium | Discair | Bronchodilator efficacy | Non-inferiority | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Equipment Design | Forced Expiratory Volume | Tiotropium Bromide - administration & dosage | Time Factors | Female | Bronchodilator Agents - adverse effects | Cholinergic Antagonists - adverse effects | Severity of Illness Index | Pulmonary Disease, Chronic Obstructive - diagnosis | Dry Powder Inhalers | Tiotropium Bromide - adverse effects | Administration, Inhalation | Treatment Outcome | Lung - physiopathology | Cholinergic Antagonists - administration & dosage | Vital Capacity | Turkey | Lung - drug effects | Aged | Pulmonary Disease, Chronic Obstructive - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text Comparative mortality risk of tiotropium administered via handihaler or respimat in COPD patients: Are they equivalent?
by Mathioudakis, Alexander G and Chatzimavridou-Grigoriadou, Victoria and Evangelopoulou, Efstathia and Mathioudakis, Georgios A and Siafakas, Nikolaos M
Pulmonary Pharmacology & Therapeutics, ISSN 1094-5539, 2014, Volume 28, Issue 2, pp. 91 - 97
Abstract Background Tiotropium bromide, once daily, long-acting anticholinergic bronchodilator is either administered by handihaler metered dose inhaler or by... 
Medical Education | Pulmonary/Respiratory | Human | Tiotropium | Respimat | Systematic review | Safety | COPD | RCT | SAMA | LABA | ICS | LAMA | SABA | RANDOMIZED CONTROLLED-TRIALS | METAANALYSIS | EFFICACY | PREVENTION | INCREASES | OBSTRUCTIVE PULMONARY-DISEASE | RESPIRATORY SYSTEM | EXACERBATIONS | PHARMACOLOGY & PHARMACY | BROMIDE | CARDIOVASCULAR SAFETY | MIST INHALER | Bronchodilator Agents - therapeutic use | Pulmonary Disease, Chronic Obstructive - mortality | Bronchodilator Agents - administration & dosage | Humans | Administration, Inhalation | Pulmonary Disease, Chronic Obstructive - physiopathology | Scopolamine Derivatives - administration & dosage | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Metered Dose Inhalers | Quality of Life | Bronchodilator Agents - adverse effects | Scopolamine Derivatives - therapeutic use | Nebulizers and Vaporizers | Scopolamine Derivatives - adverse effects | Pulmonary Disease, Chronic Obstructive - drug therapy | Tiotropium Bromide | Respiratory agents | Lung diseases, Obstructive | Comparative analysis | Patient outcomes | Mortality
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights